Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT05361694
Status
Recruiting
Apply to this trial

Conditions

  • Monoclonal Gammopathy of Undetermined Significance
  • Multiple Myeloma
  • Smoldering Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

Key Dates

Start date
Apr 12, 2022
Status verified
Apr 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Participants with MGUS or SMM
    Participants with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) will be followed for disease progression to active multiple myeloma (MM) for up to 5 years.

Primary Outcome Measure

Rate of progression to active Multiple Myeloma (MM) [ Time Frame: Up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Miami HospitalsMiamiFlorida33136
Carl Landgren, MD
[email protected]
305-243-6578
Carl Landgren, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Miami, FL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Miami Hospitals· Miami, FL

Related Studies